Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05909995 · ClinicalTrials.gov registry record · Phase 1
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05909995: Clinical Trial Phase 1 study, sponsored by Incyte Corporation.
NCT05909995 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05909995, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
Interventions
- DRUG INCB 99280 with Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-08-29 |
| Est. Completion | 2024-11-11 |
| Phase | Phase 1 |
Why NCT05909995 stopped before completion
NCT05909995 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which INCB 99280 with Ipilimumab is the first listed.
NCT05909995 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05909995 about?
NCT05909995 is a clinical study titled "Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors". The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
What is the current status of trial NCT05909995?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-08-29. Estimated completion is 2024-11-11.
What interventions are being tested in trial NCT05909995?
The interventions under investigation include: INCB 99280 with Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT05909995?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05909995's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI